Emerging Roles for von Willebrand Factor in Cancer Cell Biology

2017 ◽  
Vol 44 (02) ◽  
pp. 159-166 ◽  
Author(s):  
Roger Preston ◽  
Tracy Robson ◽  
James O'Donnell ◽  
Jamie O'Sullivan

Abstractvon Willebrand factor (VWF) is a complex multimeric plasma glycoprotein that plays critical roles in normal hemostasis. However, additional novel roles for VWF in modulating cancer cell biology, and in particular tumor metastasis, have recently been reported. Markedly elevated plasma VWF levels were associated with advanced tumor stage and metastatic disease. These observations have raised the question of whether VWF may be involved in regulating tumor progression. Interestingly, novel findings indicate that VWF is expressed by a variety of tumor cells of nonendothelial origin. Critically, tumor cells that exhibit de novo acquired VWF expression demonstrate enhanced binding to endothelial cells (EC) and platelets, and increased extravasation through EC barriers. Furthermore, in vitro studies have shown that VWF can bind a variety of different tumor cells mediated by specific receptors expressed on the tumor cell surface. The concept that VWF is important in modulating tumor metastasis is further supported by in vivo experiments demonstrating that antibody-mediated VWF inhibition significantly attenuated murine metastasis. Intriguingly, however, VWF binding to specific human tumor cell lines results in apoptosis. In this study, the authors provide an overview of recent advances supporting a role for VWF in regulating multiple aspects of cancer cell biology.

1986 ◽  
Vol 56 (01) ◽  
pp. 090-094 ◽  
Author(s):  
Kazuo Yamamoto ◽  
Hisayo Kitagawa ◽  
Kenjiro Tanoue ◽  
Takashi Tsuruo ◽  
Naomasa Yamamoto ◽  
...  

SummaryB16 mouse melanoma cell lines (B16F1, B16F10 and B16BL6) were able to induce platelet aggregation, and concomitant release of ATP in heparinized platelet-rich plasma (PRP). In citrated PRP, these tumor cells did not induce platelet aggregation. Addition of heparin to citrated PRP enabled these tumor cells to induce aggregation. In heparinized PRP, platelet aggregates induced by B16F10 cells were dissociated by the addition of either 4 mM EDTA, 10 mM CaCl2 or 0.1 μg/ml protamine sulfate. B16F10-induced aggregation in heparinized PRP was inhibited by preincubation with anti-fibronectin antibody, but not with antifibrinogen or anti-von Willebrand factor antibodies. B16F10 cells induced aggregation in washed platelet suspension with the addition of heparinized platelet-poor plasma (PPP). Cryoprecipi-tate from human plasma showed the same effect in the presence of heparin if substituted for PPP. The mixture of purified fibronectin, von Willebrand factor, fibrinogen and heparin were less effective than cryoprecipitate on B16F10-induced aggregation of washed platelets. The results suggest that an interaction between fibronectin and heparin may be important in tumor cell-induced aggregation.


2007 ◽  
Vol 120 ◽  
pp. S64-S70 ◽  
Author(s):  
Virginie Terraube ◽  
Isabelle Marx ◽  
Cécile V. Denis

2020 ◽  
Vol 2 (9) ◽  
pp. 3942-3953 ◽  
Author(s):  
Nerymar Ortiz-Otero ◽  
Jocelyn R. Marshall ◽  
Bradley W. Lash ◽  
Michael R. King

Liposomal formulation to deliver TNF-related apoptosis-inducing ligand (TRAIL) to platelets via von Willebrand Factor (vWF) interaction. TRAIL-coated platelets killed circulating tumor cells (CTCs) in the bloodstream to reduce cancer metastasis.


2006 ◽  
Vol 4 (3) ◽  
pp. 519-526 ◽  
Author(s):  
V. TERRAUBE ◽  
R. PENDU ◽  
D. BARUCH ◽  
M. F. B. G. GEBBINK ◽  
D. MEYER ◽  
...  

Oncogenesis ◽  
2018 ◽  
Vol 7 (1) ◽  
Author(s):  
Ai-jun Yang ◽  
Min Wang ◽  
Yan Wang ◽  
Wei Cai ◽  
Qiang Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document